|
ИСТИНА |
Войти в систему Регистрация |
ИПМех РАН |
||
Interlude of cGMP and cGMP/protein kinase I in pancreatic adenocarcinoma cellsстатья
Информация о цитировании статьи получена из
Web of Science,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 28 января 2015 г.
- Авторы: Karakhanova S., Golovastova M., Philippov P.P., Werner J., Bazhin A.V.
- Журнал: Pancreas
- Том: 43
- Год издания: 2014
- Издательство: Lippincott Williams & Wilkins Ltd.
- Местоположение издательства: United States
- Первая страница: 784
- Последняя страница: 794
- Аннотация: Objectives: cAMP and cGMP signalling is important both for normal and cancer cells. This signalling is controlled by adenylyl and guanylyl cyclases (GC) and cyclic nucleotide phosphodiesterases (PDE). One of the direct targets for cGMP is protein kinase G (PKG). The main aim of this work was to investigate cGMP and PKG signalling in pancreatic adenocarcinoma (PDAC) cells. Methods: PKG activity, cGMP and calcium level were measured with the CycLex Cyclic GMP dependent protein kinase (cGK) Assay Kit, the DetectX® Cyclic GMP Colorimetric EIA Kit, and the Fluo-4 NW Calcium Assay Kit, respectively. The Proteome ProfilerTM Array was done using Human Phospho-Kinase Array and Human Phospho-MAPK Array Kits. Results: This study shows for the first time that functional PKGI is expressed in PDAC cells. It demonstrates that the specific PKGI inhibitor, - DT3, induces cytotoxicity through necrosis and reduces proliferation and migration of PDAC cells. Moreover, ERK1/2 and p38 can be considered as potential targets for PKGI in PDAC cells. Additionally, the study shows that PDE and NO-GC regulate the cGMP level in PDAC cells, affecting the proliferation of the cells. Conclusions: cGMP and PKG signalling may be a target for developing new therapeutic approaches for PDAC.
- Добавил в систему: Филиппов Павел Павлович